From Pilot Project to Partnership: Expanding a Real-World Evidence Platform for Cannabis Research Through China-Brazil Collaboration

This article traces the evolution of a real-world evidence (RWE) platform for cannabis research, from its pilot phase as the "Real-World Data on the Therapeutic Response to Cannabis Products in Medical and Veterinary Practice" project in Brazil to its proposed enhancement through a strategic China-Brazil partnership. The initial pilot demonstrated the feasibility of collecting valuable data on therapeutic outcomes, product characteristics, and patient experiences. Building on this foundation, the proposed collaboration leverages China's technological expertise and Brazil's research capacity, specifically Chinese expertise in artificial intelligence (AI), big data analytics, and digital health technology infrastructure, combined with Brazilian capacity in conducting clinical studies, access to diverse patient populations, and knowledge in biodiversity, to scale the platform, incorporate advanced analytics, and harmonize regulatory frameworks, navigating the distinct regulatory landscapes of both countries, including current restrictions in China on cannabinoid use, while acknowledging its role as a major producer of industrial hemp and its growing investment in biotechnological research. This integrated approach aims to accelerate the development of evidence-based cannabis therapies and policies, fostering innovation and responsible growth within the industry, while also addressing planetary health concerns. This approach aims to align scientific advancement with ethical and sustainability considerations, reflecting a planetary health vision.